Skip to main content
Top
Published in: BMC Endocrine Disorders 1/2024

Open Access 01-12-2024 | Type 1 Diabetes | Research

Prevalence and prognosis of fulminant type 1 diabetes mellitus in The Middle East: a comparative analysis in a 5-year nationwide cohort

Authors: Fateen Ata, Adeel Ahmad Khan, Ibrahim Khamees, Sham AlKodmani, Anas Al-Sadi, Khaled Bani Yaseen, Bassam Muthanna, Angela Godwin, Stephen Frederick Beer, Mohammed Bashir

Published in: BMC Endocrine Disorders | Issue 1/2024

Login to get access

Abstract

Purpose

To analyze the prevalence and progression of fulminant type 1 diabetes (FT1D) in Qatar.

Methods

This retrospective study analyzed consecutive index- diabetic ketoacidosis (DKA) admissions (2015–2020) among patients with new-onset T1D (NT1D) in Qatar.

Results

Of the 242 patients, 2.5% fulfilled the FT1D diagnostic criteria. FT1D patients were younger (median-age 4-years vs.15-years in classic-T1D). Gender distribution in FT1D was equal, whereas the classic-T1D group showed a female predominance at 57.6% (n = 136). FT1D patients had a mean C-peptide of 0.11 ± 0.09 ng/ml, compared to 0.53 ± 0.45 ng/ml in classic-T1D. FT1D patients had a median length of stay (LOS) of 1 day (1-2.2) and a DKA duration of 11.25 h (11–15). The median (length of stay) LOS and DKA duration in classic-T1D patients were 2.5 days (1-3.9) and 15.4 h (11–23), respectively. The FT1D subset primarily consisted of moderate (83.3%) and severe 916.7%) DKA, whereas classic T1D had 25.4% mild, 60.6% moderate, and 14% severe DKA cases. FT1D was associated with a higher median white cell count (22.3 × 103/uL) at admission compared to classic T1D (10.6 × 103/uL). ICU admission was needed for 66.6% of FT1D patients, compared to 38.1% of classic-T1D patients. None of the patients in the FT1D group had mortality, while two died in the classic-T1D group.

Conclusion

This is the first study establishing the existence of FT1D in ME, which presented distinctively from classic-T1D, exhibiting earlier age onset and higher critical care requirements. However, the clinical outcomes in patients with FT1D seem similar to classic T1D.
Literature
1.
go back to reference Imagawa A, Hanafusa T, Miyagawa J, Matsuzawa Y. A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies. Osaka IDDM Study Group. N Engl J Med. 2000;342(5):301–7.CrossRefPubMed Imagawa A, Hanafusa T, Miyagawa J, Matsuzawa Y. A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies. Osaka IDDM Study Group. N Engl J Med. 2000;342(5):301–7.CrossRefPubMed
2.
go back to reference Yang D, Zhou Y, Luo S, Zheng X, Ling P, Qiu L, Xu W, Liang H, Yao B, Weng J et al. Clinical characteristics of fulminant type 1 diabetes compared with typical type 1 diabetes: one-year Follow-Up study from the Guangdong T1DM Translational Medicine Study. J Diabetes Res 2020, 2020:8726268. Yang D, Zhou Y, Luo S, Zheng X, Ling P, Qiu L, Xu W, Liang H, Yao B, Weng J et al. Clinical characteristics of fulminant type 1 diabetes compared with typical type 1 diabetes: one-year Follow-Up study from the Guangdong T1DM Translational Medicine Study. J Diabetes Res 2020, 2020:8726268.
3.
go back to reference You W, Yang J, Liu Y, Wang W, Zhu L, Wang W, Yang J, Chen F. Fulminant type 1 diabetes mellitus: two case reports. Med (Baltim). 2019;98(5):e14319.CrossRef You W, Yang J, Liu Y, Wang W, Zhu L, Wang W, Yang J, Chen F. Fulminant type 1 diabetes mellitus: two case reports. Med (Baltim). 2019;98(5):e14319.CrossRef
4.
go back to reference Luo S, Ma X, Li X, Xie Z, Zhou Z. Fulminant type 1 diabetes: a comprehensive review of an autoimmune condition. Diabetes Metab Res Rev. 2020;36(6):e3317.CrossRefPubMed Luo S, Ma X, Li X, Xie Z, Zhou Z. Fulminant type 1 diabetes: a comprehensive review of an autoimmune condition. Diabetes Metab Res Rev. 2020;36(6):e3317.CrossRefPubMed
5.
go back to reference Hosokawa Y, Hanafusa T, Imagawa A. Pathogenesis of fulminant type 1 diabetes: genes, viruses and the immune mechanism, and usefulness of patient-derived induced pluripotent stem cells for future research. J Diabetes Investig. 2019;10(5):1158–64.CrossRefPubMedPubMedCentral Hosokawa Y, Hanafusa T, Imagawa A. Pathogenesis of fulminant type 1 diabetes: genes, viruses and the immune mechanism, and usefulness of patient-derived induced pluripotent stem cells for future research. J Diabetes Investig. 2019;10(5):1158–64.CrossRefPubMedPubMedCentral
6.
go back to reference Liu L, Zeng L, Sang D, Lu Z, Shen J. Recent findings on fulminant type 1 diabetes. Diabetes Metab Res Rev 2018, 34(1). Liu L, Zeng L, Sang D, Lu Z, Shen J. Recent findings on fulminant type 1 diabetes. Diabetes Metab Res Rev 2018, 34(1).
7.
go back to reference Imagawa A, Hanafusa T, Uchigata Y, Kanatsuka A, Kawasaki E, Kobayashi T, Shimada A, Shimizu I, Toyoda T, Maruyama T, et al. Fulminant type 1 diabetes: a nationwide survey in Japan. Diabetes Care. 2003;26(8):2345–52.CrossRefPubMed Imagawa A, Hanafusa T, Uchigata Y, Kanatsuka A, Kawasaki E, Kobayashi T, Shimada A, Shimizu I, Toyoda T, Maruyama T, et al. Fulminant type 1 diabetes: a nationwide survey in Japan. Diabetes Care. 2003;26(8):2345–52.CrossRefPubMed
8.
go back to reference Cho YM, Kim JT, Ko KS, Koo BK, Yang SW, Park MH, Lee HK, Park KS. Fulminant type 1 diabetes in Korea: high prevalence among patients with adult-onset type 1 diabetes. Diabetologia. 2007;50(11):2276–9.CrossRefPubMed Cho YM, Kim JT, Ko KS, Koo BK, Yang SW, Park MH, Lee HK, Park KS. Fulminant type 1 diabetes in Korea: high prevalence among patients with adult-onset type 1 diabetes. Diabetologia. 2007;50(11):2276–9.CrossRefPubMed
9.
go back to reference Luo S, Zhang Z, Li X, Yang L, Lin J, Yan X, Wang Z, Zheng C, Huang G, Zhou Z. Fulminant type 1 diabetes: a collaborative clinical cases investigation in China. Acta Diabetol. 2013;50(1):53–9.CrossRefPubMed Luo S, Zhang Z, Li X, Yang L, Lin J, Yan X, Wang Z, Zheng C, Huang G, Zhou Z. Fulminant type 1 diabetes: a collaborative clinical cases investigation in China. Acta Diabetol. 2013;50(1):53–9.CrossRefPubMed
10.
go back to reference Zayed H. Epidemiology of diabetic ketoacidosis in arab patients with type 1 diabetes: a systematic review. Int J Clin Pract. 2016;70(3):186–95.CrossRefPubMed Zayed H. Epidemiology of diabetic ketoacidosis in arab patients with type 1 diabetes: a systematic review. Int J Clin Pract. 2016;70(3):186–95.CrossRefPubMed
11.
go back to reference De Sanctis V. Type 1 and type 2 diabetes in children and adolescents: a public health problem in Qatar. The experience of Pediatric Diabetes Center at Hamad General Hospital (HGH) of Doha. Acta Biomed. 2018;89(S5):5–6.PubMed De Sanctis V. Type 1 and type 2 diabetes in children and adolescents: a public health problem in Qatar. The experience of Pediatric Diabetes Center at Hamad General Hospital (HGH) of Doha. Acta Biomed. 2018;89(S5):5–6.PubMed
12.
go back to reference Soliman A, Alali M, Elawwa A, Elsayed N. 639 high incidence of Childhood Type 1 diabetes in Qatar between 2006 and 2011. Arch Dis Child. 2012;97(Suppl 2):A185–5.CrossRef Soliman A, Alali M, Elawwa A, Elsayed N. 639 high incidence of Childhood Type 1 diabetes in Qatar between 2006 and 2011. Arch Dis Child. 2012;97(Suppl 2):A185–5.CrossRef
13.
go back to reference Onda Y, Sugihara S, Ogata T, Yokoya S, Yokoyama T, Tajima N, Group tTDS. Incidence and prevalence of childhood-onset type 1 diabetes in Japan: the T1D study. Diabet Med. 2017;34(7):909–15.CrossRefPubMed Onda Y, Sugihara S, Ogata T, Yokoya S, Yokoyama T, Tajima N, Group tTDS. Incidence and prevalence of childhood-onset type 1 diabetes in Japan: the T1D study. Diabet Med. 2017;34(7):909–15.CrossRefPubMed
15.
go back to reference Imagawa A, Hanafusa T, Awata T, Ikegami H, Uchigata Y, Osawa H, Kawasaki E, Kawabata Y, Kobayashi T, Shimada A, et al. Report of the Committee of the Japan Diabetes Society on the Research of Fulminant and acute-onset type 1 diabetes Mellitus: New diagnostic criteria of fulminant type 1 diabetes mellitus (2012). J Diabetes Invest. 2012;3(6):536–9.CrossRef Imagawa A, Hanafusa T, Awata T, Ikegami H, Uchigata Y, Osawa H, Kawasaki E, Kawabata Y, Kobayashi T, Shimada A, et al. Report of the Committee of the Japan Diabetes Society on the Research of Fulminant and acute-onset type 1 diabetes Mellitus: New diagnostic criteria of fulminant type 1 diabetes mellitus (2012). J Diabetes Invest. 2012;3(6):536–9.CrossRef
16.
go back to reference Rudd B, Patel K, Levy N, Dhatariya K. A survey of the implementation of the NHS diabetes guidelines for management of Diabetic Ketoacidosis in the Intensive Care units of the East of England. J Intensive Care Soc. 2013;14(1):60–4.CrossRef Rudd B, Patel K, Levy N, Dhatariya K. A survey of the implementation of the NHS diabetes guidelines for management of Diabetic Ketoacidosis in the Intensive Care units of the East of England. J Intensive Care Soc. 2013;14(1):60–4.CrossRef
17.
go back to reference Imagawa A, Hanafusa T. Fulminant type 1 diabetes—East and West. The Journal of Clinical Endocrinology & Metabolism; 2023. Imagawa A, Hanafusa T. Fulminant type 1 diabetes—East and West. The Journal of Clinical Endocrinology & Metabolism; 2023.
18.
go back to reference Sims EK, Mirmira RG, Evans-Molina C. The role of beta-cell dysfunction in early type 1 diabetes. Curr Opin Endocrinol Diabetes Obes. 2020;27(4):215–24.CrossRefPubMedPubMedCentral Sims EK, Mirmira RG, Evans-Molina C. The role of beta-cell dysfunction in early type 1 diabetes. Curr Opin Endocrinol Diabetes Obes. 2020;27(4):215–24.CrossRefPubMedPubMedCentral
19.
go back to reference Ehehalt S, Gauger N, Blumenstock G, Feldhahn L, Scheffner T, Schweizer R, Neu A. Hemoglobin A1c is a reliable criterion for diagnosing type 1 diabetes in childhood and adolescence. Pediatr Diabetes. 2010;11(7):446–9.CrossRefPubMed Ehehalt S, Gauger N, Blumenstock G, Feldhahn L, Scheffner T, Schweizer R, Neu A. Hemoglobin A1c is a reliable criterion for diagnosing type 1 diabetes in childhood and adolescence. Pediatr Diabetes. 2010;11(7):446–9.CrossRefPubMed
20.
go back to reference Qiu J, Yin W, Wang R, Luo S, Zhou Z. Fulminant type 1 diabetes: focusing on triggering factors. Diabetes Metab Res Rev 2023:e3731. Qiu J, Yin W, Wang R, Luo S, Zhou Z. Fulminant type 1 diabetes: focusing on triggering factors. Diabetes Metab Res Rev 2023:e3731.
21.
go back to reference Hanafusa T, Imagawa A. Fulminant type 1 diabetes: a novel clinical entity requiring special attention by all medical practitioners. Nat Clin Pract Endocrinol Metab. 2007;3(1):36–45.CrossRefPubMed Hanafusa T, Imagawa A. Fulminant type 1 diabetes: a novel clinical entity requiring special attention by all medical practitioners. Nat Clin Pract Endocrinol Metab. 2007;3(1):36–45.CrossRefPubMed
Metadata
Title
Prevalence and prognosis of fulminant type 1 diabetes mellitus in The Middle East: a comparative analysis in a 5-year nationwide cohort
Authors
Fateen Ata
Adeel Ahmad Khan
Ibrahim Khamees
Sham AlKodmani
Anas Al-Sadi
Khaled Bani Yaseen
Bassam Muthanna
Angela Godwin
Stephen Frederick Beer
Mohammed Bashir
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Endocrine Disorders / Issue 1/2024
Electronic ISSN: 1472-6823
DOI
https://doi.org/10.1186/s12902-024-01559-8

Other articles of this Issue 1/2024

BMC Endocrine Disorders 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.